Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

ConclusionsMEDI0680 induced peripheral T-cell proliferation and increased plasma IFN γ and associated chemokines regardless of clinical response. CD8+ T-cell tumor infiltration and tumoral gene expression ofIFNG, CD8A,CXCL9, and granzyme K (GZMK) were also increased following MEDI0680 administration.Trial registrationNCT02013804; date of registration December 12, 2013.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research